Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers

Clinical Pharmacokinetics

Volumn 46, Issue 7, 2007, Pages 589-598

  Martin, David E ^a   Blum, Robert ^b   Doto, Judy ^a   Galbraith, Hal ^c   Ballow, Charles ^b  

^a Panacos Pharmaceuticals   (United States)

^b Buffalo Clinical Research Center   (United States)

^c IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O (3,3 DIMETHYLSUCCINYL)BETULIC ACID; 6BETA HYDROXYHYDROCORTISONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HYDROCORTISONE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; LEG CRAMP; LOADING DRUG DOSE; LOOSE FECES; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; VIROGENESIS; VIRUS INHIBITION;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALF-LIFE; HEADACHE; HIV-1; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NAUSEA; SUCCINATES; TIME FACTORS; TRITERPENES;

EID: 34347370621     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746070-00004     Document Type: Article

References (14)

1. Fox J, Dustan S, McClure M, et al. Transmitted drug-resistant HIV-1 in primary HIV-1 infection: incidence, evolution and impact on response to antiretroviral therapy. HIV Med 2006 Oct; 7 (7): 477-83
2. Jayaraman GC, Archibald CP, Kim J, et al. PA population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006 May; 42 (1): 86-90
3. Oette M, Kaiser R, Daumer M, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006 Apr 15; 41 (5): 573-81
4. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94
5. Deeks SG. Antiretroviral treatment of HIV infected adults. BMJ 2006; 332: 1489-93
6. Blaise P, Clevenbergh P, Vaira D, et al. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin Belg 2002; 57: 191-201
7. Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 2003; 100: 13555-60
8. Kilgore N, Reddick M, Zuiderhof M, et al. The first-in-class maturation inhibitor, PA-457, is a potent inhibitor of HIV-1 drug-resistant isolates and acts synergistically with approved HIV drugs in vitro [abstract no. 509]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8; Denver (CO)
9. Martin DE, Ballow CH, Blum R, et al. The safety, tolerability and pharmacokinetics of PA-457, a first-in-class HIV maturation inhibitor, in healthy volunteers [abstract no. P312]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14-18; Glasgow
10. Martin DE, Smith P, Wild C, et al. In vitro and in vivo disposition of BVM, a novel inhibitor of HIV-1 maturation [abstract WePeA5644]. 15th Annual International AIDS Conference; 2004 Jul 11-16; Bangkok
11. Kovacs SJ, Martin DE, Everitt DF, et al. Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998; 63: 617-22
12. Tran JQ, Kovacs SJ, McIntosh TS, et al. Morning spot and 24 hour urinary 6β-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 1999; 39: 487-94
13. Smith P, Forrest A, Beatty, et al. Pharmacokinetics/pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV-infected patients [abstract no. 52]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8; Denver (CO)
14. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30